Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.34, $0.31 worse than the analyst estimate of $1.65. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.45 billion.

GUIDANCE:

Gilead Sciences sees FY2023 EPS of $6.45-$6.80, versus the consensus of $6.73. Gilead Sciences sees FY2023 revenue of $26.3-26.7 billion, versus the consensus of $26.663 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.